Corrine Savill - Jan 22, 2024 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)

Role
Chief Business Officer
Signature
/s/ Jacquelyn Sumer, Attorney-in-Fact
Stock symbol
CGEM
Transactions as of
Jan 22, 2024
Transactions value $
-$338,246
Form type
4
Date filed
1/24/2024, 05:00 PM
Previous filing
Feb 21, 2023
Next filing
Jan 30, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CGEM Common Stock Options Exercise $62.6K +14.6K +8.56% $4.30 185K Jan 22, 2024 Direct
transaction CGEM Common Stock Sale -$177K -14.6K -7.88% $12.18 170K Jan 22, 2024 Direct F1, F2
transaction CGEM Common Stock Sale -$49.6K -4.13K -2.42% $12.02 166K Jan 22, 2024 Direct F1, F3
transaction CGEM Common Stock Options Exercise $91.7K +21.3K +12.84% $4.30 187K Jan 23, 2024 Direct
transaction CGEM Common Stock Sale -$266K -21.3K -11.38% $12.46 166K Jan 23, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -14.6K -29.19% $0.00 35.3K Jan 22, 2024 Common Stock 14.6K $4.30 Direct F5
transaction CGEM Stock Option (Right to Buy) Options Exercise $0 -21.3K -60.36% $0.00 14K Jan 23, 2024 Common Stock 21.3K $4.30 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 7, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.44. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.00 to $12.09. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $12.16 to $12.60. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 25% of the shares vested on May 4, 2020, and the remaining shares vested in 36 equal monthly installments thereafter, becoming fully vested and exercisable on May 4, 2023.